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Chapter l I
S{.JMMARY AND CONCLUSIONS
In this thesis several aspects of anti-cancer therapy have been described. Despite the
application of many forms of chemo- or immunotherapy in many tumor types, most
patients are not curable yet. However, since the introduction of platinum-containing
multidrug regimens for the treatment of patients with disseminated germ-cell cancer,
this type of cancer has become a model for a curable neoplasm. In the Introduction,
the current treatment of disseminated germ-cell cancer of the testis is described and
several research questions regarding the efficacy and toxicity of chemotherapeutic
regimens for this kind of cancer are formulated. Some of the side-effècts oÍ
bleomycin, a widely applied drug in the treatment of disseminated germ-cell cancer,
seem to be related to induction of tumor necrosis factor-a (TNF). Because TNF can
also act as an anti-tumor agent, research questions are formulated addressing the
Íèasibility of TNF as an anti-tumor agent, particularly in drug-resistant umor cell
l ines.
Chapter I describes the efficacy and toxicity of a combination regimen
consisting of cyclophosphamide, vincristine, and carboplatin, a cisplatin analogue,
(COC) for the treatment of advanced seminoma on an outpatient basis. Twenty-seven
patients of which 6 had been treated previously with radiotherapy, received four
cycles with chemotherapy at 3-week intervals. A complete response (CR) was
observed in 6 patients (95% confidence interval (Cl), 6-38%), a partial response
(PR) in 19 patients (95% Cl, 5I-88%) and in 2 patients (95% U, 0-18%) only a
decline in tumor markers was seen whereas no reduction in retroperitoneal mass
occurred. Post-chemotherapeutic masses were not surgically removed or irradiated.
Two patients have died after a median follow-up of 26 months (range 5-69 months)
yielding 93% of the patients with no evidence of disease, a figure equivalent to that
achieved by other polychemotherapeutic regimens in this patient population. Main
toxicity was haematological with 100% of the patients experiencing leucocytopenia
grade III/IV and 81% thrombocytopenia grade III/IV. Non-haematological side-
eÍïects were rare. In conclusion, COC is an effective regimen for the treatment of
advanced seminoma with the advantage that it can be applied on an outpatient basis.
In the future, its main toxicity, myelosuppression, may be partly prevented by the
addition of growth factors.
However, despite the successful application of chemotherapy in the treatment
of disseminated germ-cell cancer, there are still patients who either do not achieve a
t2l
condition of no evidence of disease or relapse afïer an initial response. By salvage
chemotherapy, even some of these patients can be cured. In chapter 2, a small study
is presented on the eÍïicacy and toxicity of such a salvage treatment. Eight patients
with relapsed non-seminomatous testicular cancer after primary cisplatin-containing
chemotherapy were treated with high dose methotrexate, vincristine, and cisplatin.
Two patients obtained a complete response (CR) (43t and 53* months), 2 a partial
response (PR), whereas no alterations in tumor mass or tumor markers were
observed in the other 4 patients. Toxicity was mainly due to methotrexate and could
be ameliorated to a large extent by leucovorin. In conclusion, this salvage therapy
yields a response rate equivalent with that achieved by other salvage regimens and
has considerablc ant i - rumor act iv i ty  in  pat ients wi th re lapsed non-seminomatous
germ-cell cancer with manageable side-eÍfects.
The main drawback of the application of chemotherapy is the occurrence of
side-eÍÍects. In the treatment of disseminated germ-cell cancer, bleomycin is a
cytotoxic drug used in many regimens and is Íèared for its induction of bleomycin-
induced pneumonitis (BIP) which is sometimes fatal. Therefore, it is important to
detect pulmonary alterations due to bleomycin early. Because bleomycin is nowadays
only applied as part of a rnultidrug regimen and not as a single agent, it is not
possible to establish pulmonary Íunction tests which are specific Íbr bleomycin-
induced pulmonary changes. The study described in chapter 3 was performed to
establish the changes in pulmonary function in good risk patients with disseminated
non-seminomatous germ-cell cancer randomised to receive treatment with four cycles
of either etoposide, and cisplatin (EP) (27 patients) or etoposide and cisplatin with
the addition of 30 mg bleomycin i.v. weekly for 12 weeks (BEP) (27 patients). This
enabled us to determine whether lung function assessments are specifically afÍected
by bleomycin. Lung Íunctions determined beÍbre and at 3-week intervals during
chemotherapy, consisted of the transfèr capacity of the lungs for carbon monoxide
(Tr.u), the diÍlusing capacity of the alveolo-capillary membrane (DM), the pulmonary
capillary blood volurne (Vc), the transf'er capacity of the lungs for carbon monoxide
per unit alveolar volume (IQo), and the slow inspiratory vital capacity (VC). During
treatment, both groups showed a decline in T16e, Dr, and IQo, but differences in
these parameters between the groups were not recorded. However, the VC and V.
decreased significantly in the patients during treatment with BEP, but remained
constant in the EP group. Therefore, it could be concluded that the T,-.o, Dr, and
K.o are not proper tools to detect pulmonary damage by bleomycin as part of this
multidrug chemotherapeutic regimen. VC and V. however, are pulmonary Íunction
tests which reÍ1ect specifically pulmonary alterations due to bleomycin.
In the treatment of non-seminomatous germ-cell cancer, bleomycin is often
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C by the kidneys and
cisplatin is nephrotoxic leading to a change in pharmacokinetics of bleomycin, the
combination of these two agents not only yields a more effective anti-tumor activity
but may also enhance the bleomycin-induced pulmonary toxicity. In chapter 4, we
explored whether a decrease in renal function due to cisplatin augmented bleomycin-
induced pulmonary function in a group of patients with non-seminomatous testicular
cancer receiving etoposide, and cisplatin with (BEP) or without bleomycin (EP).
Before and at 3-week intervals during treatment, creatinine clearance and pulmonary
functions were determined. Compared to pretreatment, both groups showed a similar
decline in renal function which was attributed to the use of cisplatin. In the BEP
group, the decrease in renal function was significantly correlated with a decrease in
the transfer capacity of the lungs for carbon monoxide (Tr.o) and the vital capacity
(VC), parameters known to reflect bleomycin-induced pulmonary toxicity. Other
pulmonary functions studied did not correlate with renal function. ln the 27 patients
receiving etoposide and cisplatin (EP) being the control group, no relationships
between changes in renal function and pulmonary function assessments were
observed at all. These data suggest hat there is indeed an augmented toxic effect of
bleomycin on the lungs when renal function is impaired. ThereÍbre, special attention
for the development of bleomycin-induced pulmonary toxicity should be paid when
bleomycin is combined with a nephrotoxic agent such as cisplatin.
Besides pulmonary toxicity, the application of bleomycin is also featured by
the occurrence of acute side-eÍfects uch as fèver, chills, and hypotension observed
directly aÍter administration of this agent. There are several indications that
induction of cytokines by bleomycin is involved in the development of these acute
side-effects as well as in the induction of pulmonary damage. In chapter 5, the
effect of bleomycin inÍusion on circulating levels of the cytokines tumor necrosis
factor-a (TNF), interleukin-lB (IL-18), and transforming growth factor-B (TGFB) is
studied in 14 patients receiving 30 mg bleomycin infused in 15 minutes. Compared
to pretreatment, the mean TNF plasma level appeared to be increased significantly
3, 4.5, and 24 hours after administration. No effects of bleomcyin were observed on
levels of IL-18 and TGFB. These data suggest hat induction of cytokines, and TNF
in particular, is indeed involved in the pathogenesis of bleomycin-induced side-
eÍïects.
Besides being a mediator of side-effects, TNF has also the ability to act as an
anti-cancer agent. As an single agent TNF possesses anti-tumor activity against a
wide range of tumor cell types whereas non-transformed cells are relatively resistant.
The observation that in animals TNF is also active as an anti-tumor agent, raised
high expectations for its clinical application. However, phase I and II trials with
TNF as single agent were featured by severe side-effects and almost no anti-tumor
activity. Recently, the interest in TNF was revived. In the setting of hyperthermic
L./- 3
isolated limb perÍ-usion (HILP), TNF combined with the alkylating agent melphalan
resulted in dramatic anti-tumor eÍfects against melanomas and sarcomas, tumors
known to be highly resistant o cytotoxic agents. A review on TNF as anticancer
agent is presented in chapter 6.
In vitro. the relationship between resistance of tumor cell l ines to cytotoxic
agents and sensitivity to TNF has been the subject of many studies. For tumor cell
l ines resistant to doxorubicin, a widely used anti-cancer drug, both resistance and an
increased sensitivity to TNF has been described. The mechanism responsible for the
latter phenomenon is unclear. In chapter 7, we explored the relationship between
TNF-sensitivity and doxorubucin-resistance in our widely examined doxorubucin-
resistant cell line panel consisting of the parental cell line GLC* and its sublines
GLCo-Adr., and GLCo-4dr,.,,* with respective resistance factors of 2- and 350-fbld.
One of the mechanisms responsible for the doxorubucin-resistance in GLC.-Adr,*
and GLC*-Adr..,,* is a decreased topoisomerase IIa gene copy number resulting in a
decreased topoisomerase IIa protein level, the target of doxorubucin. In our study,
we Íbund that GLC. was almost complete resistant to TNF, whereas a maxtmum
growth inhibition of 31 % and 68% was observed in GLC.-Adr,^ and GLCo-Adr.,.,,*
respectively. In these cell lines, sensitivity to TNF appeared to correlate inversely
with topoisomerase IIa expression and gene copies. In the proximity of the
topoisomerase IIa gene on chromosome l7q is located the gene encoding for c-
erbB2 which product is a known cause for TNF-resistance. We demonstrate that
GLC*-Adr., and GLC''-Adr.r,,* which have compared to GLC, a decreased
topoisomerase IIo gene copy number, have a simultaneous lower number of c-erbB2
eene copies (l5o/c and 65% of GLC. respectively), probably due to physical l inkage
between these two genes. During exposure of GLC. to doxorubucin to establish
GLCo-Adr,, and GLCo-Adr,.,,*, this linkage resulted not only in cell lines with
decreased topoisomerase IIcv 
-qene copy numbers but also with reduced c-erbB2 gene
copies. This reduced number of c-erbB2 gene copies in GLCo-Adrr* and GLCr-
Adr.r,,, leads to a decreased c-erbB2 expression (55% and 35% oÍ GLC4) and
subsequently in increased sensitivity to TNF. Furthermore, we established some of
the mechanisms associated with c-erbB2 overexpression resulting in TNF-resistance
in GLC'. We found that compared with the TNF-sensitive GLCo-Adrr.,,*, GLC. had
a 5-Íbld increased bcl-2 expression and probably a decreased TNF-receptor
Íunctionality, both factors known to confer resistance to TNF. These in vitro
experiments suggest enhanced efficacy of TNF in tumor cell lines resistant to
doxorubucin yielding a possible tool to circumvent drug-resistance.
In vitro, TNF exerts its cytotoxicity at least partly by induction of apoptosis.
One of the most important genes mediating apoptosis is the tumor suppressor gene
p53. Wild-type p53 (wtp53) is induced after DNA-damage resulting in either
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apoptosis or Gl and G2iM-cell cycle arrest facilitating DNA-repair. In about 50-
60% of the human tumors, the gene encoding Íbr p53 is mutated. This mutated p53
(mtp53) may aÍïect the normal function of p53 and subsequently alter the sensitivity
of these tumors to cytotoxic agents. In chapter 8 we establish the effect of p53
status on sensitivity to TNF in a model consisting of a human ovarian carcinoma cell
line containing wtp53 transfected with a control plasmid (A2780/cmv) or with a
plasmid constirutively expressing a commonly occurring fbrm of mtp53
(421801m248). We found that A2780/cmv was relatively insensitive to TNF
(maximum growth inhibition 30%), whereas A278O1m248 showed increased
susceptibility for TNF (maximum growth inhibition 67%). Exploring the
mechanisms responsible for the enhanced sensitivity of a mtp53 containing ntmor
cell line revealed that compared to A2780 lcmv, A27801m248 had a reduced
expression of p53-dependent genes such as bcl-2 and c-erbB2 (42% and 54% of
42780/cmv respectively), both factors known to conÍèr TNF-resistance. ThereÍbre,
it is concluded that p53 status can indeed affect sensitivity to TNF and that reduced
expression of p53-dependent genes resulting in resistance to TNF, may be
responsible for the enhanced sensitivity to TNF in the mtp53-containing cell line.
Clinical as well as preclinical evidence suggests that TNF is able to overcome
drug resistance in tumors. In order to elucidate whether TNF is able to do so in
tumor cell lines which are resistant due to a mutation in the tumor suppressor gene
p53, we established in chapter 9 the in vitro combined cytotoxic eff'ects of TNF
with various cytotoxic agents in a model consisting of a human ovarian cancer cell
line containing wtp53 and sublines which were made resistant to various agents by
transfection of a mutated p53. We Íbund that compared to the control cell line
42780/cmv, two sublines containing mtp53 showed increased resistance against
various cytotoxic agents but also collateral sensitivity to TNF. The interaction of
TNF with the cytotoxic agents tested was similar in drug-sensitive as well as drug-
resistant cell lines. However, due to increased sensitivity in 42780/m248 to TNF at
the dose used for the combinations, the combination of TNF with several cytotoxic
drugs reduced the level of resistance against these cytotoxic agents in 427801m248
compared to the control cell line A2780/cmv. So, in conclusion, this study shows
that addition of TNF can ameliorate resistance to cytotoxic agents in tumor cell lines
resistant due to the presence of mtp53. This reduction in resistance by TNF is not
due to synergistic interaction, but to collateral sensitivity to TNF in drug-resistant
cel lines, a phenomenon which has been described in several other reports.
Besides preclinical studies as described in chapter 7-9, also clinical studies
exploring TNF as an anti-tumor agent in the setting of hyperthermic limb perfusion
(HILP) showed that TNF is active against chemotherapy-resistant tumors.
Furthermore, these studies of HILP with TNF and melphalan revealed that by
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applying intensive care technology, higher systemic TNF levels can be reached than
previously reported in phase I trials administrating TNF systemically. Based on these
observations, it might be feasible by applying such technology to administer
systemically TNF in high doses in combination with cytotoxic drugs to patients with
disseminated cancer. However, it is important before initiating such studies to
establish the effects of such high doses of TNF in combination with cytotoxic drugs
on vital organs such as the lungs. In chapter 10, the impact on the lungs of such a
treatment was studied by performing pulmonary function assessments in 12 patients
before and after HILP with TNF and melphalan. Due to leakage during perfusion,
systemic TNF levels were reached up to 356 ng/ml. Significant alterations in the
vital capacity (VC), the capillary blood volume (Vc), the diffusing capacity of the
alveolo-capillary membrane (Dm), and the transfer capacity of the lungs for carbon
monoxide per unit alveolar volume (IQo) were observed I week after HILP. Eight
weeks after perfusion all disturbances had returned to pretreatment level. Alterations
in pulmonary function one week after perfusion were not related to maximum TNF-
levels. In conclusion, this study shows that high systemic TNF-levels in combination
with melphalan causes transient pulmonary function disturbances. These disturbances
which are probably partly caused by the high systemic TNF levels, return to
pretreatment level eight weeks after treatment. Therefore, these results would not
preclude further studies on the feasibility of TNF as a systemic agent with a starting
dose level to be calculated from the leakage serum levels.
We can therefore conclude that TNF, being a mediator of some of the side-
effects of bleomycin, also can be used to circumvent drug-resistance in tumor cells.
Furthermore, toxicity of high doses of systemically administered TNF can be
managed adequately in the future by applying intensive care technology.
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